Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Signs $728 Million Deal Granting Rights for Anti-PD-1 in 21 Countries to Dr. Reddy’s

publication date: May 8, 2023

Shanghai Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to India’s Dr. Reddy’s Labs in a deal worth up to $728 million. Junshi’s toripalimab is approved for six indications in China. Dr. Reddy’s will own rights to the drug in Latin America, India and South Africa, with potential to add Australia, New Zealand and nine other countries. The company also bought an exclusive right of first negotiation for commercialization of two other Junshi products. Junshi is testing toripalimab, the first domestic anti-PD-1 mAb approved for commercialization in China, for 15 indications globally. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here